MedTrace Logo

FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD

NCT04311281 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-05-06

No results posted yet for this study

Summary

The primary objective of this study is to demonstrate the safety and efficacy of positron emission tomography (PET) imaging with a radioactive compound called \[F-18\]FDDNP in subjects with suspected Alzheimer's disease or suspected chronic traumatic encephalopathy (CTE) to predict clinical decline after one and two years.

Conditions

  • Suspected Chronic Traumatic Encephalopathy (CTE) or Traumatic Encephalopathy Syndrome (TES)
  • Suspected Alzheimer's Disease (AD)

Interventions

BIOLOGICAL

[F-18]FDDNP-PET

\[F-18\]FDDNP, or 2-(1-{6-\[(2-\[F-18\]fluoroethyl)(methyl)amino\]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.

Sponsors & Collaborators

Principal Investigators

  • Helen Lavretsky, MD · University of California, Los Angeles, Semel Institute

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-31
Primary Completion
2021-05-03
Completion
2021-05-03
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04311281 on ClinicalTrials.gov